BIOINFORMA TICS

0'so;112u110}u101q//2duq

SIBumoprOJX

£10"

an?kgowsmomammowoxmoa‘ocgawbmﬁ

 

C. Yau

 

ACKNOWLEDGEMENTS

Thanks to A. Halpern (Complete Genomics) who provided the
simulated normal—cancer mixtures sequence data and A. Schuh
for the CLL data. Thanks to JiB. Cazier for comments and
discussions.

Conﬂict of Interest: none declared.

REFERENCES

Barretina,J. et a]. (2012) The Cancer Cell Line Encyclopaedia enables predictive
modelling of anticancer drug sensitivity. Nature, 483, 6037607.

Beroukhim,R. et a]. (2010) The landscape of somatic copy—number alteration across
human cancers. Nature, 463, 8997905.

Boeva,V. et a]. (2012) Control—FREEC: a tool for assessing copy number and allelic
content using next—generation sequencing data. Bioinformutiex, 28, 4234125.

Collisson,E.A. et a]. (2012) What are we learning from the cancer genome? Nat. Rev.
Clin. 0111301., 9, 621$30.

Complete Genomics. (2012) http://www.completegenomics.com/public—data/cancer—
data/ (10 October 2011, date last accessed).

Ha,G. et a]. (2012) Integrative analysis of genome—wide loss of heterozygosity and
monoallelic expression at nucleotide resolution reveals disrupted pathways in
triple—negative breast cancer. Genome Re.\‘., 22, 199572007.

Schuh,A. et a]. (2012) Monitoring chronic lymphocytic leukemia progression by
whole genome sequencing reveals heterogeneous clonal evolution patterns.
Blood, 120, 41914196.

Yau,C. et a]. (2010) A statistical approach for detecting genomic aberrations in
heterogeneous tumor samples from single nucleotide polymorphism genotyping
data. Genome Biol, 11, R92.

Xi,R. et a]. (2010) BIC—seq: a fast algorithm for detection of copy number alter—
ations based on high—throughput sequencing data. Genome Biol, 11 (Suppl. 1),
010.

 

2484

/3.IO'S[BIIInO[p.IOJXO'SOlJBLUJOJIIlOlq/ﬂduq

